Clinical Trial Update: Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating ruxolitinib as add-on therapy for steroid-refractory graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Steroid Refractory Gvhd

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Yi-Lun Wang | Conditions: Steroid Refractory GVHD | Phase 3 | Status: COMPLETED